Teclistamab and Daratumumab Display Promise in Relapsed Multiple Myeloma

A combination therapy of teclistamab and daratumumab demonstrated significant efficacy in patients with relapsed or refractory multiple myeloma, according to results published February 19, 2026, in the New England Journal of Medicine. The study, detailed in a paper spanning pages 763-772 of Volume 394, Issue 8, offers a potential new treatment option for a challenging patient population.

The research focused on individuals whose multiple myeloma had returned after, or failed to respond to, prior treatments. Multiple myeloma is a cancer that forms in white blood cells called plasma cells. The trial evaluated the safety and effectiveness of combining teclistamab, a bispecific antibody targeting BCMA and CD3, with daratumumab, a monoclonal antibody directed against CD38.

The New England Journal of Medicine publication coincides with a separate report in the journal concerning an Image Challenge, published on the same date, February 19, 2026, which presented a clinical case of a 26-year-old man with fever, nausea, and vomiting. While unrelated to the myeloma study, the simultaneous publication highlights the journal’s ongoing role in presenting diverse medical cases and research.

BioVersys, in collaboration with its partners, also had phase 2a tuberculosis trial results published in the New England Journal of Medicine on February 19, 2026, according to a report from finanznachrichten.de. This indicates a particularly active publication schedule for the journal on that date.

The study details the clinical outcomes of patients receiving the teclistamab and daratumumab combination. Further details regarding specific response rates and duration of response are contained within the full publication in the New England Journal of Medicine. The research team assessed the treatment’s impact on disease progression and overall survival.

The New England Journal of Medicine has recently published several issues, including Volume 394, No. 6 (February 5, 2026) and Volume 394, No. 7 (February 12, 2026), preceding the February 19th issue featuring the myeloma trial results.

The FDA’s evolving approval processes were also recently discussed in the New England Journal of Medicine, with a focus on the increasing reliance on single pivotal trials as the new default option for approval. This context may influence the regulatory pathway for teclistamab and daratumumab as a combination therapy.

The long-term effects of the combination therapy and potential resistance mechanisms remain areas of ongoing investigation. Researchers are continuing to monitor patients enrolled in the trial to gather further data on the durability of the response and identify factors that may predict treatment success.

The FDA has not yet issued a statement regarding the potential approval of the teclistamab and daratumumab combination for relapsed or refractory multiple myeloma.